Dear EditorAn association between the use of contraceptives containing exogenous oestrogen compounds and subsequent diagnosis for malignant melanoma (MM) has been suspected for decades. This is, in part, due to the finding that oestrogen stimulates melanogenesis and the observation that the incidence of MM is greater in women vs. men before the age of 50, but lower than in men after the age of 50, corresponding with the average age of menopause when oestrogen levels dramatically decrease.Prior studies assessing the relationship between the incidence of MM and exposure to exogenous oestrogen provide conflicting results. Moreover, the vast majority of previous reports do not specify the oestrogen‐based dosage form, nor the actual dose of the oestrogenic compound, and typically rely on patient completed questionnaires that are subject to recall bias. Further, over recent decades, the dosage of oestrogenic compounds in hormonal contraceptives has greatly decreased compared to studies of the earliest oestrogenic compounds where an association with MM was reported. Given widespread and chronic use, the aim of this study was to determine whether exposure to contraceptives containing ethinylestradiol (EE) at microdoses (40mcg/day or less) showed an association with MM within a large, urban, Midwestern U.S. patient population served by
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud